Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | DCLL9718S |
Synonyms | |
Therapy Description |
DCLL9718S is an antibody-drug conjugate (ADC) consisting of an anti-CLL1 antibody linked by a disulfide linker to two pyrrolobenzodiazepine drugs (PMID: 33617672). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
DCLL9718S | RG6109|DCLL 9718S|RG 6109|RG-6109|DCLL-9718S | DCLL9718S is an antibody-drug conjugate (ADC) consisting of an anti-CLL1 antibody linked by a disulfide linker to two pyrrolobenzodiazepine drugs (PMID: 33617672). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03298516 | Phase I | DCLL9718S Azacitidine + DCLL9718S | A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy | Completed | USA | CAN | 0 |